EcoDrugPlus

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSDCDG00000004035
Gene Symbol: CHRM3
3 Cross references
188 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSDCDG00000025758
Gene Symbol: CHRM3
3 Cross references
187 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSDCDG00000018968
Gene Symbol: CHRM4
3 Cross references
186 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSDCDG00000023900
Gene Symbol: CHRM5
3 Cross references
190 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSDCDG00000023409
Gene Symbol: CHRNA3
3 Cross references
201 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSDCDG00000026890
Gene Symbol: CHRNA3
3 Cross references
201 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSDCDG00000034425
Gene Symbol: CHRNB2
3 Cross references
198 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSDCDG00000026897
Gene Symbol: CHRNB4
3 Cross references
193 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSDCDG00000005542
Gene Symbol: F2R
3 Cross references
211 Possible Orthologues:

Coagulation Factor Vii-Like

Ensembl ID : ENSDCDG00000035158
Gene Symbol: LOC114764480
3 Cross references
203 Possible Orthologues:

Coagulation Factor X-Like

Ensembl ID : ENSDCDG00000035118
Gene Symbol: LOC114764479
3 Cross references
246 Possible Orthologues:

Coiled-Coil Domain-Containing Protein 6-Like

Ensembl ID : ENSDCDG00000005161
Gene Symbol: LOC114778604
3 Cross references
151 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).